Castle Biosciences (NASDAQ:CSTL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $37.00 to $50.00. They now have a "buy" rating on the stock.
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Is New Uveal Melanoma Data Elevating Castle Biosciences' DecisionDx-UM Platform Story (CSTL)? [Yahoo! Finance]
Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
Castle Biosciences (CSTL): Valuation Check After Expert Panel Endorses DecisionDx-Melanoma Test [Yahoo! Finance]